← Back to Clinical Trials
Recruiting NCT05590494

NCT05590494 Novel Treatment for Rotator Cuff Tears

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05590494
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Supraspinatus Tear
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2022-11-07
Primary Completion 2028-12

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Ultrasonic tenotomy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 15 participants in total. It began in 2022-11-07 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The focus of this study is to examine changes in pain scores, strength, and range of motion over time following an ultrasonic tenotomy on a partial tear (\<50%) of the supraspinatus tendon of the rotator cuff.

Eligibility Criteria

Inclusion Criteria: \- Evidence of partial tear (\< 50%) of the supraspinatus tendon on MRI. Exclusion Criteria: * A tear of the supraspinatus tendon greater \> 50% and any areas of full thickness tearing, concomitant tears \> 25% of other rotator cuff tendons (infraspinatus, teres minor or subscapularis), or acute tear of the glenoid labrum. * Evidence of systemic illness/infection requiring oral or IV antibiotics during the recruitment period. * Evidence of overlying skin infection or lesion at the proposed device insertion point on the shoulder. * Previous corticosteroid injection within three months. * Those individuals less than 25 and greater than 75 years of age will be excluded.

Contact & Investigator

Principal Investigator

Jacob Erickson, DO

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT05590494 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 75 Years, studying Supraspinatus Tear. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05590494 currently recruiting?

Yes, NCT05590494 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.

Where is the NCT05590494 trial being conducted?

This trial is being conducted at Onalaska, United States.

Who is sponsoring the NCT05590494 clinical trial?

NCT05590494 is sponsored by Mayo Clinic. The principal investigator is Jacob Erickson, DO at Mayo Clinic. The trial plans to enroll 15 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology